Xellia Pharmaceuticals USA LLC
15 drugs in NADAC|15 Generic,0 Brand
Xellia Pharmaceuticals USA LLC lists 15 NDCs in the CMS NADAC file (15 generic, 0 brand), at an average NADAC of $12.19 per unit, with a week-over-week move of +2.0% across products that moved. The firm's full portfolio, pricing trend are listed below.
Total Drugs
15
15G / 0B
Avg Price / Unit
$12.1891
$0.05 – $28.77
Avg 7d Change
+2.04%
Across 4 drugs with changes
7d Activity
of 15 total drugs
Portfolio Price Trend
Monthly average NADAC price across all drugs
Keep following this manufacturer
These next-step links connect the manufacturer page to the markets, classes, and trend views most likely to deepen research.
Lead market
Daptomycin market
See the molecule this manufacturer shows up in most often and compare it against competing suppliers.
Lead class
Lipopeptide Antibacterial therapeutic class
Review the broader class where Xellia Pharmaceuticals USA LLC has the strongest current portfolio footprint.
Trend hub
Portfolio trend view
Jump to the trend hub to compare this manufacturer against the rest of the market on weekly price movement.
Guide
NADAC pricing primer
Use the explainer for context on the benchmark this manufacturer is being compared against.
Frequently Asked Questions
How many drugs does Xellia Pharmaceuticals USA LLC make?
Xellia Pharmaceuticals USA LLC lists 15 NDCs in the CMS NADAC file — 15 generic and 0 brand products.
What is the average price of Xellia Pharmaceuticals USA LLC drugs?
The average NADAC across Xellia Pharmaceuticals USA LLC's portfolio is $12.1891 per unit, ranging from $0.0479 to $28.7741.
What types of drugs does Xellia Pharmaceuticals USA LLC make?
Xellia Pharmaceuticals USA LLC makes drugs across 7 FDA pharmacologic classes. The most common by NDC count are Lipopeptide Antibacterial (5), Polymyxin-class Antibacterial (2), Penem Antibacterial (2), Glycopeptide Antibacterial (2), Amide Local Anesthetic (2).
Has Xellia Pharmaceuticals USA LLC had any drug recalls?
No FDA enforcement recalls are matched to Xellia Pharmaceuticals USA LLC in the openFDA feed.
How has Xellia Pharmaceuticals USA LLC's pricing changed recently?
Over the past 7 days, 3 Xellia Pharmaceuticals USA LLC products rose and 1 fell, with a portfolio-wide average change of +2.0%.
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
VORICONAZOLE 200 MG VIAL Voriconazole | $28.7741 per EA | — |
DAPTOMYCIN 500 MG VIAL Daptomycin | $23.7984 per EA | +4.90% |
DAPTOMYCIN 500 MG VIAL Daptomycin | $23.7984 per EA | +4.90% |
DAPTOMYCIN 500 MG VIAL daptomycin | $20.7686 per EA | — |
COLISTIMETHATE 150 MG VIAL colistimethate sodium | $15.4867 per EA | — |
COLISTIMETHATE 150 MG VIAL colistimethate sodium | $15.4867 per EA | — |
SUMATRIPTAN 6 MG/0.5 ML VIAL SUMATRIPTAN SUCCINATE | $14.9345 per ML | -2.05% |
DAPTOMYCIN 350 MG VIAL daptomycin | $13.4180 per EA | — |
DAPTOMYCIN 350 MG VIAL Daptomycin | $13.4180 per EA | — |
MEROPENEM IV 1 GM VIAL MEROPENEM | $4.6875 per EA | +0.40% |
VANCOMYCIN 1 GM VIAL vancomycin hydrochloride | $2.9591 per EA | — |
MEROPENEM IV 500 MG VIAL MEROPENEM | $2.8678 per EA | — |
VANCOMYCIN 500 MG VIAL vancomycin hydrochloride | $2.3054 per EA | — |
BUPIVACAINE 0.5% VIAL Bupivacaine Hydrochloride | $0.0860 per ML | — |
BUPIVACAINE 0.25% VIAL Bupivacaine Hydrochloride | $0.0479 per ML | — |